Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells
Kamran Ghoreschi, Jürgen Brück, Christina Kellerer, Caishu Deng, Haiyan Peng, Oliver Rothfuss, Rehana Z Hussain, Anne R Gocke, Annedore Respa, Ivana Glocova, Nadejda Valtcheva, Eva Alexander, Susanne Feil, Robert Feil, Klaus Schulze-Osthoff, Rudolf A Rupec, Amy E Lovett-Racke, Ralf Dringen, Michael K Racke, Martin Röcken, Kamran Ghoreschi, Jürgen Brück, Christina Kellerer, Caishu Deng, Haiyan Peng, Oliver Rothfuss, Rehana Z Hussain, Anne R Gocke, Annedore Respa, Ivana Glocova, Nadejda Valtcheva, Eva Alexander, Susanne Feil, Robert Feil, Klaus Schulze-Osthoff, Rudolf A Rupec, Amy E Lovett-Racke, Ralf Dringen, Michael K Racke, Martin Röcken
Abstract
Fumarates improve multiple sclerosis (MS) and psoriasis, two diseases in which both IL-12 and IL-23 promote pathogenic T helper (Th) cell differentiation. However, both diseases show opposing responses to most established therapies. First, we show in humans that fumarate treatment induces IL-4-producing Th2 cells in vivo and generates type II dendritic cells (DCs) that produce IL-10 instead of IL-12 and IL-23. In mice, fumarates also generate type II DCs that induce IL-4-producing Th2 cells in vitro and in vivo and protect mice from experimental autoimmune encephalomyelitis. Type II DCs result from fumarate-induced glutathione (GSH) depletion, followed by increased hemoxygenase-1 (HO-1) expression and impaired STAT1 phosphorylation. Induced HO-1 is cleaved, whereupon the N-terminal fragment of HO-1 translocates into the nucleus and interacts with AP-1 and NF-κB sites of the IL-23p19 promoter. This interaction prevents IL-23p19 transcription without affecting IL-12p35, whereas STAT1 inactivation prevents IL-12p35 transcription without affecting IL-23p19. As a consequence, GSH depletion by small molecules such as fumarates induces type II DCs in mice and in humans that ameliorate inflammatory autoimmune diseases. This therapeutic approach improves Th1- and Th17-mediated autoimmune diseases such as psoriasis and MS by interfering with IL-12 and IL-23 production.
Figures
References
- Altmeyer P.J., Matthes U., Pawlak F., Hoffmann K., Frosch P.J., Ruppert P., Wassilew S.W., Horn T., Kreysel H.W., Lutz G., et al. 1994. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J. Am. Acad. Dermatol. 30:977–981 10.1016/S0190-9622(94)70121-0
- Arbiser J.L. 2011. Fumarate esters as angiogenesis inhibitors: key to action in psoriasis? J. Invest. Dermatol. 131:1189–1191 10.1038/jid.2011.45
- Axtell R.C., de Jong B.A., Boniface K., van der Voort L.F., Bhat R., De Sarno P., Naves R., Han M., Zhong F., Castellanos J.G., et al. 2010. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat. Med. 16:406–412 10.1038/nm.2110
- Becher B., Durell B.G., Noelle R.J. 2002. Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. J. Clin. Invest. 110:493–497
- Bettelli E., Sullivan B., Szabo S.J., Sobel R.A., Glimcher L.H., Kuchroo V.K. 2004. Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis. J. Exp. Med. 200:79–87 10.1084/jem.20031819
- Biedermann T., Mailhammer R., Mai A., Sander C., Ogilvie A., Brombacher F., Maier K., Levine A.D., Röcken M. 2001a. Reversal of established delayed type hypersensitivity reactions following therapy with IL-4 or antigen-specific Th2 cells. Eur. J. Immunol. 31:1582–1591 10.1002/1521-4141(200105)31:5<1582::AID-IMMU1582>;2-M
- Biedermann T., Zimmermann S., Himmelrich H., Gumy A., Egeter O., Sakrauski A.K., Seegmüller I., Voigt H., Launois P., Levine A.D., et al. 2001b. IL-4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB/c mice. Nat. Immunol. 2:1054–1060 10.1038/ni725
- Burton P.R., Clayton D.G., Cardon L.R., Craddock N., Deloukas P., Duncanson A., Kwiatkowski D.P., McCarthy M.I., Ouwehand W.H., Samani N.J., et al. 2007. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat. Genet. 39:1329–1337 10.1038/ng.2007.17
- Carmody R.J., Ruan Q., Liou H.-C., Chen Y.H. 2007. Essential roles of c-Rel in TLR-induced IL-23 p19 gene expression in dendritic cells. J. Immunol. 178:186–191
- Chora A.A., Fontoura P., Cunha A., Pais T.F., Cardoso S., Ho P.P., Lee L.Y., Sobel R.A., Steinman L., Soares M.P. 2007. Heme oxygenase-1 and carbon monoxide suppress autoimmune neuroinflammation. J. Clin. Invest. 117:438–447 10.1172/JCI28844
- de Jong R., Bezemer A.C., Zomerdijk T.P., van de Pouw-Kraan T., Ottenhoff T.H., Nibbering P.H. 1996. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur. J. Immunol. 26:2067–2074 10.1002/eji.1830260916
- Dringen R., Hamprecht B. 1996. Glutathione content as an indicator for the presence of metabolic pathways of amino acids in astroglial cultures. J. Neurochem. 67:1375–1382 10.1046/j.1471-4159.1996.67041375.x
- Dudziak D., Kamphorst A.O., Heidkamp G.F., Buchholz V.R., Trumpfheller C., Yamazaki S., Cheong C., Liu K., Lee H.W., Park C.G., et al. 2007. Differential antigen processing by dendritic cell subsets in vivo. Science. 315:107–111 10.1126/science.1136080
- Durchdewald M., Beyer T.A., Johnson D.A., Johnson J.A., Werner S., auf dem Keller U. 2007. Electrophilic chemicals but not UV irradiation or reactive oxygen species activate Nrf2 in keratinocytes in vitro and in vivo. J. Invest. Dermatol. 127:646–653 10.1038/sj.jid.5700585
- Frohman E.M., Racke M.K., Raine C.S. 2006. Multiple sclerosis—the plaque and its pathogenesis. N. Engl. J. Med. 354:942–955 10.1056/NEJMra052130
- Gautier G., Humbert M., Deauvieau F., Scuiller M., Hiscott J., Bates E.E., Trinchieri G., Caux C., Garrone P. 2005. A type I interferon autocrine–paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J. Exp. Med. 201:1435–1446 10.1084/jem.20041964
- Ghashghaeinia M., Bobbala D., Wieder T., Koka S., Brück J., Fehrenbacher B., Röcken M., Schaller M., Lang F., Ghoreschi K. 2010. Targeting glutathione by dimethylfumarate protects against experimental malaria by enhancing erythrocyte cell membrane scrambling. Am. J. Physiol. Cell Physiol. 299:C791–C804 10.1152/ajpcell.00014.2010
- Ghoreschi K., Mrowietz U., Röcken M. 2003a. A molecule solves psoriasis? Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses. J. Mol. Med. 81:471–480 10.1007/s00109-003-0460-9
- Ghoreschi K., Thomas P., Breit S., Dugas M., Mailhammer R., van Eden W., van der Zee R., Biedermann T., Prinz J., Mack M., et al. 2003b. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat. Med. 9:40–46 10.1038/nm804
- Gilliland F.D., Li Y.F., Saxon A., Diaz-Sanchez D. 2004. Effect of glutathione-S-transferase M1 and P1 genotypes on xenobiotic enhancement of allergic responses: randomised, placebo-controlled crossover study. Lancet. 363:119–125 10.1016/S0140-6736(03)15262-2
- Graupner V., Alexander E., Overkamp T., Rothfuss O., De Laurenzi V., Gillissen B.F., Daniel P.T., Schulze-Osthoff K., Essmann F. 2011. Differential regulation of the proapoptotic multidomain protein Bak by p53 and p73 at the promoter level. Cell Death Differ. 18:1130–1139 10.1038/cdd.2010.179
- Hegazi R.A., Rao K.N., Mayle A., Sepulveda A.R., Otterbein L.E., Plevy S.E. 2005. Carbon monoxide ameliorates chronic murine colitis through a heme oxygenase 1–dependent pathway. J. Exp. Med. 202:1703–1713 10.1084/jem.20051047
- Jeannin P., Delneste Y., Lecoanet-Henchoz S., Gauchat J.F., Life P., Holmes D., Bonnefoy J.Y. 1995. Thiols decrease human interleukin (IL) 4 production and IL-4-induced immunoglobulin synthesis. J. Exp. Med. 182:1785–1792 10.1084/jem.182.6.1785
- Kappos L., Gold R., Miller D.H., Macmanus D.G., Havrdova E., Limmroth V., Polman C.H., Schmierer K., Yousry T.A., Yang M., et al. 2008. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 372:1463–1472 10.1016/S0140-6736(08)61619-0
- Kapsenberg M.L. 2003. Dendritic-cell control of pathogen-driven T-cell polarization. Nat. Rev. Immunol. 3:984–993 10.1038/nri1246
- Keyse S.M., Tyrrell R.M. 1989. Heme oxygenase is the major 32-kDa stress protein induced in human skin fibroblasts by UVA radiation, hydrogen peroxide, and sodium arsenite. Proc. Natl. Acad. Sci. USA. 86:99–103 10.1073/pnas.86.1.99
- Kim H.S., Cho I.H., Kim J.E., Shin Y.J., Jeon J.H., Kim Y., Yang Y.M., Lee K.H., Lee J.W., Lee W.J., et al. 2008. Ethyl pyruvate has an anti-inflammatory effect by inhibiting ROS-dependent STAT signaling in activated microglia. Free Radic. Biol. Med. 45:950–963 10.1016/j.freeradbiomed.2008.06.009
- Kneilling M., Mailhammer R., Hültner L., Schönberger T., Fuchs K., Schaller M., Bukala D., Massberg S., Sander C.A., Braumüller H., et al. 2009. Direct crosstalk between mast cell-TNF and TNFR1-expressing endothelia mediates local tissue inflammation. Blood. 114:1696–1706 10.1182/blood-2008-11-187682
- Kortylewski M., Xin H., Kujawski M., Lee H., Liu Y., Harris T., Drake C., Pardoll D., Yu H. 2009. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell. 15:114–123 10.1016/j.ccr.2008.12.018
- Krueger G.G., Langley R.G., Leonardi C., Yeilding N., Guzzo C., Wang Y., Dooley L.T., Lebwohl M. 2007. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N. Engl. J. Med. 356:580–592 10.1056/NEJMoa062382
- Lehmann J.C., Listopad J.J., Rentzsch C.U., Igney F.H., von Bonin A., Hennekes H.H., Asadullah K., Docke W.D. 2007. Dimethylfumarate induces immunosuppression via glutathione depletion and subsequent induction of heme oxygenase 1. J. Invest. Dermatol. 127:835–845 10.1038/sj.jid.5700686
- Lin Q., Weis S., Yang G., Weng Y.-H., Helston R., Rish K., Smith A., Bordner J., Polte T., Gaunitz F., Dennery P.A. 2007. Heme oxygenase-1 protein localizes to the nucleus and activates transcription factors important in oxidative stress. J. Biol. Chem. 282:20621–20633 10.1074/jbc.M607954200
- Linker R.A., Lee D.H., Ryan S., van Dam A.M., Conrad R., Bista P., Zeng W., Hronowsky X., Buko A., Chollate S., et al. 2011. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain. 134:678–692 10.1093/brain/awq386
- Litjens N.H., Nibbering P.H., Barrois A.J., Zomerdijk T.P., Van Den Oudenrijn A.C., Noz K.C., Rademaker M., Van De Meide P.H., Van Dissel J.T., Thio B. 2003. Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with downregulation of type 1 cytokines. Br. J. Dermatol. 148:444–451 10.1046/j.1365-2133.2003.05153.x
- Litjens N.H., Rademaker M., Ravensbergen B., Rea D., van der Plas M.J., Thio B., Walding A., van Dissel J.T., Nibbering P.H. 2004. Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses. Eur. J. Immunol. 34:565–575 10.1002/eji.200324174
- Liu J., Guan X., Tamura T., Ozato K., Ma X. 2004. Synergistic activation of interleukin-12 p35 gene transcription by interferon regulatory factor-1 and interferon consensus sequence-binding protein. J. Biol. Chem. 279:55609–55617 10.1074/jbc.M406565200
- Liu W., Ouyang X., Yang J., Liu J., Li Q., Gu Y., Fukata M., Lin T., He J.C., Abreu M., et al. 2009. AP-1 activated by toll-like receptors regulates expression of IL-23 p19. J. Biol. Chem. 284:24006–24016 10.1074/jbc.M109.025528
- Loewe R., Holnthoner W., Gröger M., Pillinger M., Gruber F., Mechtcheriakova D., Hofer E., Wolff K., Petzelbauer P. 2002. Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells. J. Immunol. 168:4781–4787
- Lutz M.B., Kukutsch N., Ogilvie A.L., Rössner S., Koch F., Romani N., Schuler G. 1999. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods. 223:77–92 10.1016/S0022-1759(98)00204-X
- Mazzoni A., Segal D.M. 2004. Controlling the Toll road to dendritic cell polarization. J. Leukoc. Biol. 75:721–730 10.1189/jlb.1003482
- Menges M., Rössner S., Voigtländer C., Schindler H., Kukutsch N.A., Bogdan C., Erb K., Schuler G., Lutz M.B. 2002. Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity. J. Exp. Med. 195:15–21 10.1084/jem.20011341
- Mise-Omata S., Kuroda E., Niikura J., Yamashita U., Obata Y., Doi T.S. 2007. A proximal kappaB site in the IL-23 p19 promoter is responsible for RelA- and c-Rel-dependent transcription. J. Immunol. 179:6596–6603
- Mrowietz U., Asadullah K. 2005. Dimethylfumarate for psoriasis: more than a dietary curiosity. Trends Mol. Med. 11:43–48 10.1016/j.molmed.2004.11.003
- Nair R.P., Duffin K.C., Helms C., Ding J., Stuart P.E., Goldgar D., Gudjonsson J.E., Li Y., Tejasvi T., Feng B.J., et al. 2009. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat. Genet. 41:199–204 10.1038/ng.311
- Nakahira K., Kim H.P., Geng X.H., Nakao A., Wang X., Murase N., Drain P.F., Wang X., Sasidhar M., Nabel E.G., et al. 2006. Carbon monoxide differentially inhibits TLR signaling pathways by regulating ROS-induced trafficking of TLRs to lipid rafts. J. Exp. Med. 203:2377–2389 10.1084/jem.20060845
- Napolitani G., Rinaldi A., Bertoni F., Sallusto F., Lanzavecchia A. 2005. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 6:769–776 10.1038/ni1223
- Nestle F.O., Kaplan D.H., Barker J. 2009. Psoriasis. N. Engl. J. Med. 361:496–509 10.1056/NEJMra0804595
- Peterson J.D., Herzenberg L.A., Vasquez K., Waltenbaugh C. 1998. Glutathione levels in antigen-presenting cells modulate Th1 versus Th2 response patterns. Proc. Natl. Acad. Sci. USA. 95:3071–3076 10.1073/pnas.95.6.3071
- Polman C.H., O’Connor P.W., Havrdova E., Hutchinson M., Kappos L., Miller D.H., Phillips J.T., Lublin F.D., Giovannoni G., Wajgt A., et al. 2006. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354:899–910 10.1056/NEJMoa044397
- Racke M.K., Bonomo A., Scott D.E., Cannella B., Levine A., Raine C.S., Shevach E.M., Röcken M. 1994. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J. Exp. Med. 180:1961–1966 10.1084/jem.180.5.1961
- Rothfuss O., Fischer H., Hasegawa T., Maisel M., Leitner P., Miesel F., Sharma M., Bornemann A., Berg D., Gasser T., Patenge N. 2009. Parkin protects mitochondrial genome integrity and supports mitochondrial DNA repair. Hum. Mol. Genet. 18:3832–3850 10.1093/hmg/ddp327
- Schilling S., Goelz S., Linker R., Luehder F., Gold R. 2006. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin. Exp. Immunol. 145:101–107 10.1111/j.1365-2249.2006.03094.x
- Schuler G., Schuler-Thurner B., Steinman R.M. 2003. The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol. 15:138–147 10.1016/S0952-7915(03)00015-3
- Segal B.M., Constantinescu C.S., Raychaudhuri A., Kim L., Fidelus-Gort R., Kasper L.H. 2008. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 7:796–804 10.1016/S1474-4422(08)70173-X
- Tzima S., Victoratos P., Kranidioti K., Alexiou M., Kollias G. 2009. Myeloid heme oxygenase–1 regulates innate immunity and autoimmunity by modulating IFN-β production. J. Exp. Med. 206:1167–1179 10.1084/jem.20081582
- Weber M.S., Prod’homme T., Youssef S., Dunn S.E., Rundle C.D., Lee L., Patarroyo J.C., Stüve O., Sobel R.A., Steinman L., Zamvil S.S. 2007. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat. Med. 13:935–943 10.1038/nm1620
- Zhu C., Rao K., Xiong H., Gagnidze K., Li F., Horvath C., Plevy S. 2003. Activation of the murine interleukin-12 p40 promoter by functional interactions between NFAT and ICSBP. J. Biol. Chem. 278:39372–39382 10.1074/jbc.M306441200
Source: PubMed